{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-036742","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2024-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.288915+00:00","generated_at":"2026-06-04T11:29:03.036688+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Annovis Bio completes data cleaning for phase II/III Alzheimer's study; topline data expected April 2024","bullets":["Data cleaning completed for phase II/III trial of buntanetap in mild to moderate Alzheimer's disease.","Topline efficacy results expected in April 2024.","Study enrolled 353 patients; 327 completed; three doses (7.5, 15, 30 mg) vs placebo over 12 weeks.","All patients received standard of care in addition to buntanetap or placebo."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-036742","json":"https://secwatch.observer/filing/0001104659-24-036742.json","markdown":"https://secwatch.observer/filing/0001104659-24-036742.md","text":"https://secwatch.observer/filing/0001104659-24-036742.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924036742/0001104659-24-036742-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924036742/tm249369d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T11:29:03.036688+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}